title: The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
abstract: Phosphodiesterase-5 (PDE-5) inhibitors selectively inhibit PDE-5 enzymes that are present in various tissues like penile tissue, platelets, vascular, and smooth muscle tissue. The drug's actions on these tissues have lead to the successful therapeutic use in patients suffering from conditions such as erectile dysfunction (ED) and pulmonary hypertension. PDE-5 inhibitors (PDE-5i) act on the erectile tissue causing penile smooth muscle relaxation and vasodilatation leading to penile erection. In addition, in particular when used in conjunction with prostaglandin inhibitors, PDE-5i cause vasodilatation in pulmonary vasculature hence decreasing both the pulmonary arterial pressure and resistance. PDE-5i have also shown to mildly decrease blood pressure, increase cardiac index, and increase coronary blood flow in experimental animals as well as in human studies. The Food and Drug Administration (FDA) has approved three PDE-5i for the treatment of ED: sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) and one for pulmonary hypertension: sildenafil (Revatio). These agents are highly selective for PDE-5 enzymes as compared to other subclasses of PDE enzymes and have the almost identical pharmacological action but slightly different pharmacokinetics. Only little data exist about long-term use of PDE-5i and their effects on different organ system. This paper reviews the current information available on chronic PDE-5 inhibitor use.
authors.affiliation: Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. schwarze@cshs.org
authors.forename: E R
authors.initials: ER
authors.lastname: Schwarz
authors.forename: V
authors.initials: V
authors.lastname: Kapur
authors.forename: J
authors.initials: J
authors.lastname: Rodriguez
authors.forename: S
authors.initials: S
authors.lastname: Rastogi
authors.forename: S
authors.initials: S
authors.lastname: Rosanio
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000367:Age Factors; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D041981:Gastrointestinal Tract / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D008168:Lung / Q000187:drug effects; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D010726:Phosphodiesterase Inhibitors; D015106:3',5'-Cyclic-GMP Phosphodiesterases